EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Giulia Martini; Claudia Cardone; Pietro Paolo Vitiello; Valentina Belli; Stefania Napolitano; Teresa Troiani; Davide Ciardiello; Carminia Maria Della Corte; Floriana Morgillo; Nunzia Matrone; Vincenzo Sforza; Gianpaolo Papaccio; Vincenzo Desiderio; Mariel C. Paul; Verónica Moreno‐Viedma; Nicola Normanno; Anna Maria Rachiglio; Virginia Tirino; Evaristo Maiello; Tiziana Pia Latiano; Daniele Rizzi; Giuseppe Signoriello; Maria Sibilia; Fortunato Ciardiello; Erika Martinelli

doi:10.1158/1535-7163.mct-18-0539

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

primary and acquired resistance to anti-EGFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Martini et al. (2019) studied this question.

synapsesocial.com/papers/6a01df3a3718553b53cae771 https://doi.org/10.1158/1535-7163.mct-18-0539

View Full Paper

Ask AI

Bookmark

Share

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading